Annovis Bio, Inc. filed a Form 8-K on October 30, 2026, disclosing that it received a notice from the New York Stock Exchange on October 29, 2026, stating the company is no longer in compliance with NYSE continued listing standards under Section 802.01B of the NYSE Listed Company Manual.

Key Highlights

  • Non-compliance trigger: The NYSE notified Annovis Bio that its 30 trading-day average market capitalization was approximately $48.4 million as of October 28, 2026, below the $50 million threshold required by Section 802.01B.
  • Stockholders' deficit: The company's last reported stockholders' deficit as of June 30, 2026 was approximately $(4.3) million, also below the $50 million stockholders' equity requirement.
  • Cure period: The company has 45 days from the notice to submit a remediation plan to the NYSE, and up to 9 months from receipt of the notice to regain compliance.
  • Continued listing during cure: The common stock will remain listed and traded on the NYSE under the symbol "ANVS" during the cure period, with a ".BC" designation added to indicate below-criteria status.
  • No immediate business impact: According to the filing, the notice "does not affect the Company's business operations or its reporting obligations" and "does not conflict with or cause an event of default under any of the Company's material debt or other agreements."
  • Delisting risk: If the plan is not submitted timely, not accepted, or the company fails to comply, the NYSE will initiate suspension and delisting procedures; the NYSE may also take accelerated action if the stock trades below $0.10.

Annovis Bio Faces NYSE Listing Standards Review After Market Cap Falls Below $50 Million

According to the Form 8-K filed with the Securities and Exchange Commission, Annovis Bio, Inc. (NYSE:ANVS) received a written notice from the New York Stock Exchange on October 29, 2026, indicating the company is out of compliance with Section 802.01B of the NYSE Listed Company Manual. The rule requires that a listed company maintain either an average market capitalization of at least $50 million over a consecutive 30 trading-day period, or stockholders' equity of at least $50 million. The filing states that Annovis Bio met neither condition, with its 30-day average market capitalization at approximately $48.4 million and a stockholders' deficit of approximately $(4.3) million as of June 30, 2026.

The filing discloses that Annovis Bio has notified the NYSE of its intent to submit a remediation plan within 45 days of the notice. The NYSE will then have 45 days to evaluate whether the plan demonstrates a reasonable ability to return to compliance within a 9-month cure period. During this time, the company's shares will continue trading on the NYSE, but with a ".BC" suffix appended to the ticker to signal below-criteria status. The filing notes the ".BC" designation will be removed once compliance is regained.

The filing cautions that if the company's plan is not submitted on time or is rejected by the NYSE, delisting proceedings will be initiated. The NYSE may also pursue accelerated delisting if the stock trades at levels it views as "abnormally low," which the filing states the NYSE "generally views" as trading below $0.10 per share. Semi-annual reviews are required throughout the cure period to confirm adherence to the plan. The filing includes forward-looking statements, which the company characterizes as subject to inherent uncertainties and risks, including its ability to develop and execute a compliance plan.

What Was Disclosed

Annovis Bio disclosed receipt of an NYSE non-compliance notice on October 29, 2026, related to Section 802.01B, citing a 30-day average market cap of approximately $48.4 million and a stockholders' deficit of approximately $(4.3) million. The company has 45 days to submit a remediation plan and up to 9 months to regain compliance.